Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Potential side effects include anaphylaxis and infusion-related reactions such as rash and diarrhea. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. Gilead and Merck will share global development and commercialization costs 60% and 40%, respectively, while having an equal share of the therapy's sales until the revenue crosses certain milestones.
Gilead's misinternalization  had 59% of the voting power.
( z0 have :ARG0 ( z1 internalize :ARG0 ( z2 person :name ( z3 name :op "Gilead" ) ) ) :ARG1 ( z4 power :ARG1-of ( z5 include :ARG2 ( z6 power :mod ( z7 vote ) ) :ARG3 ( z8 percentage-entity :value 59 ) ) ) )
(z0 / have-03
    :ARG0 (z1 / internalize-01
              :ARG0 (z2 / person
                        :name (z3 / name
                                  :op1 "Gilead")))
    :ARG1 (z4 / power
              :ARG1-of (z5 / include-91
                           :ARG2 (z6 / power
                                     :mod (z7 / vote-01))
                           :ARG3 (z8 / percentage-entity
                                     :value 59))))
Gilead 's misinternalization had 59 % of the voting power .
z2 :name z3
z3 :op1 1
z1 :ARG0 z2
z0 :ARG0 z1
z8 :value 0
z5 :ARG3 z8
z4 :ARG1-of z5
z0 :ARG1 z4
z6 :mod z7
z5 :ARG2 z6